Fri 03/10/2023 11:52 AM
Share this article:
Aenova reported a 9.3% drop in adjusted EBITDA for 2022 despite a strong recovery in the final quarter after being unable to pass through surging input costs in full. The German pharma contract development and manufacturing organization, or CDMO, is budgeting EBITDA to grow 7.4% in 2023, however it expects free cash flow to remain negative as a result of rising interest costs, sources said.

Sales reached €749.2 million in 2022, just short of €752.4 million budgeted but up 7.5%
Share this article:
This article is an example of the content you may receive if you subscribe to a product of Reorg Research, Inc. or one of its affiliates (collectively, “Reorg”). The information contained herein should not be construed as legal, investment, accounting or other professional services advice on any subject. Reorg, its affiliates, officers, directors, partners and employees expressly disclaim all liability in respect to actions taken or not taken based on any or all the contents of this publication. Copyright © 2023 Reorg Research, Inc. All rights reserved.
Thank you for signing up
for Reorg on the Record!